How Miaoling's pLV3-CMV-OVAL(chicken)-CopGFP-Puro (P43339) Helped Researchers Uncover How Valosin-Containing Protein (VCP) Regulates CD8+ T Cells in the Tumor Microenvironment
4 min readLiterature Reference
· Journal: Signal Transduction and Targeted Therapy (Nature Portfolio)
· Publication Date: January 2025
· Impact Factor: 40.8
· Article Title: VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+ T cells function in the HCC microenvironment
· DOI: 10.1038/s41392-024-02120-8
· Original Article: https://doi.org/10.1038/s41392-024-02120-8
Study Overview
The research team found that CD8+ T cells, key effectors of antitumor immunity, often exhibit impaired function in the tumor microenvironment (TME) of patients with hepatocellular carcinoma (HCC). Their findings showed that valosin-containing protein (VCP) suppresses CD8+ T-cell activation, expansion, and cytotoxic activity, thereby weakening the immune system's ability to eliminate HCC cells.
CD8+ T-cell activation depends on antigen recognition and stimulation. Chicken ovalbumin (OVA), a widely used model antigen in biomedical research, provides a practical tool for studying antigen-specific immune responses. To better model the HCC immune microenvironment in mice, the researchers generated a stable Hepa 1-6 cell line overexpressing OVA (Hepa 1-6-OVA). These tumor cells were then co-cultured with CD8+ T cells, allowing OVA expression to support antigen-specific T-cell activation.
The results showed that when VCP expression was knocked down in Hepa 1-6-OVA cells, both direct-contact and Transwell-based non-contact co-culture experiments revealed fewer apoptotic CD8+ T cells and a higher proportion of apoptotic tumor cells than in the control group. In sequential culture experiments using conditioned medium from the tumor cells, CD8+ T-cell proliferation and cytokine levels also increased significantly when VCP expression was reduced. These findings support a role for VCP-associated downstream metabolic signaling in suppressing CD8+ T-cell function and expansion.
To establish a stable cell model for these experiments, the research team consulted with Miaoling Biotechnology and selected plasmid P0268 (pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro) as the starting vector. This was used to develop P43339 (pLV3-CMV-OVAL(chicken)-CopGFP-Puro), a lentiviral vector designed to support OVA overexpression in Hepa 1-6 cells.
Key Experimental Evidence
Plasmids Used in the Study
The Plasmids section of the article's Materials and Methods explicitly identifies the following plasmids as being sourced from Miaoling Biotechnology:
· pCMV-His-UB (P4836)
· pLV3-CMV-OVAL(chicken)-CopGFP-Puro (P43339)
These plasmids supported the experimental work investigating VCP-associated mechanisms and CD8+ T-cell function in the HCC microenvironment.
Co-Culture Experiments Reveal the Effects of VCP on CD8+ T Cells
In the section investigating how VCP regulates CD8+ T-cell function, the researchers co-cultured CD8+ T cells with OVA-expressing Hepa 1-6 cells (Hepa 1-6-OVA).
The results showed that loss of Vcp in tumor cells enhanced CD8+ T-cell cytotoxicity, increased tumor-cell apoptosis, reduced CD8+ T-cell apoptosis, and increased the levels of the cytotoxic effector molecule granzyme B (GzmB) and the cytokine interferon-gamma (IFN-γ). These findings were consistent with the team's in vivo observations.
After CD8+ T cells migrate from lymph nodes into tumors, they can recognize tumor-associated antigens presented by tumor cells and mediate tumor-cell killing. To determine whether VCP also affected antigen presentation, the researchers performed non-contact co-culture experiments using a Transwell system.
The results showed that Vcp depletion in tumor cells still increased tumor-cell apoptosis, reduced CD8+ T-cell apoptosis, and promoted CD8+ T-cell proliferation and cytokine expression. These findings suggest that the observed effects were not solely attributable to changes in direct cell-to-cell contact or tumor antigen presentation.
The Role of pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro (P0268) in the Experimental Workflow
Flexible Cloning and Transgene Expression
The pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro vector provides a multiple cloning site (MCS) for inserting a gene of interest and supports transgene expression under the CMV promoter. Its lentiviral backbone enables the generation of stable cell models in compatible cell types, making it useful for experiments that require sustained expression of a target protein.
Fluorescent Tracking for More Efficient Screening
The vector carries CopGFP, enabling researchers to monitor fluorescent protein expression and help identify cells that have received and expressed the vector-derived construct. This offers a convenient way to assess transduction and expression during preliminary screening, reducing reliance on additional assays at early stages.
Fluorescence alone, however, does not confirm the identity or functional activity of the target protein. Additional validation, such as PCR, immunoblotting, or sequencing, may still be needed depending on the experimental objective.
Lentiviral Delivery for Stable Cell-Line Generation
The lentiviral vector backbone supports packaging into lentiviral particles for gene delivery. Following optimization of the packaging and transduction conditions, this approach can facilitate the generation of stable cell lines expressing the gene of interest.
In this study, the resulting OVA-overexpressing Hepa 1-6 model provided a platform for co-culture experiments designed to investigate how VCP-associated metabolic pathways affect CD8+ T-cell responses in the HCC microenvironment.
By helping researchers establish a suitable antigen-expressing tumor-cell model, Miaoling's plasmid resources supported an experimental workflow for studying tumor–immune interactions and the mechanisms underlying impaired antitumor immunity.
https://www.miaolingbio.net
Wuhan MiaoLing Biotechnology Co., Ltd.
About Author
